Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2014

View Archived Issues

Innovative Medicines Initiative launches project to develop antibiotics for Gram-negative pathogens

GSK reports approvals and developments of fourth quarter 2013

Antibody DNA barcoding used for protein analysis of fine-needle aspirates

EluSys Therapeutics presents promising results for the anthrax anti-toxin ETI-204

Researchers at Roche disclose novel modulators of neurogenesis

Dermira provides progress update for three programs

Glenmark Pharmaceuticals prepares new TRPC6 antagonists

Generex provides update on phase II AE-37 trial in breast cancer

Merck & Co. discloses novel DPP IV inhibitors

Celon Pharma patents new PDE9 inhibitors for neurodegenerative disorders

Ventrus Biosciences reports results from second phase III trial of diltiazem cream

New company Voyager Therapeutics to develop gene therapies for CNS disorders

Promising results reported for 4SC-202 in phase I trials

Pharmacyclics gains FDA approval for use of Imbruvica in new indication

Novel PADI4 inhibitors synthesized at GlaxoSmithKline

Kissei and Alteogen form business collaboration

Cabozantinib shows clinical activity in phase II trials in patients with urothelial carcinoma

Eisai to launch Pariet triple formulation combination packs for H. pylori eradication in Japan

Direct lineage reprogramming of mammalian neuronal and non-neuronal cells into neurons

FDA requests additional safety studies for DURECT's Posidur

The discovery and characterization of novel agents for the treatment of influenza

Alvogen launches biosimilar monoclonal antibody therapy in Central and Eastern Europe

FDA committee recommends against approval of cangrelor

Biodel reports preliminary results from phase I trial of concentrated insulin BIOD-531

Bayer completes decentralized registration procedure in E.U. for low-dose contraceptive patch

Sedia Biosciences receives phase II funding from NIH for HIV-1 assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...